Terns Pharmaceuticals, Inc. (TERN)

8,95 -0,56 (-5,84%) Alla chiusura: 04:00PM EDT

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Boulevard
Suite 100
Foster City, CA 94404
United States
650 525 5535
https://www.ternspharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 66

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Mark Joseph Vignola Ph.D.	CFO & Treasurer	974,16k	N/D	1978
Ms. Amy L. Burroughs M.B.A.	CEO & Director	N/D	N/D	1970
Ms. Elona Kogan Esq., J.D.	Chief Legal Officer	N/D	N/D	1969
Dr. Jeffrey R. Jasper Ph.D.	Senior Vice President of Research	N/D	N/D	N/D
Dr. Emil T. Kuriakose M.D.	Chief Medical Officer	N/D	N/D	1980
Ms. Melita Sun Jung	Chief Business Officer	N/D	N/D	1977
Mr. Scott Harris	Chief Development Officer	N/D	N/D	N/D
Ms. Debra Sieminski	Senior Vice President of Medical Affairs	N/D	N/D	N/D
Ms. Pamela Danagher	Senior Vice President of Regulatory Affairs & Quality Assurance	N/D	N/D	N/D
Mr. David Eric Strauss	VP of Finance & Controller	N/D	N/D	1986

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Governance aziendale

L'ISS Governance QualityScore di Terns Pharmaceuticals, Inc. al 1 settembre 2024 è 7. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.